Search clinical trials for: discontinuation treatment TKI

Total 63385 results

Poitiers University Hospital

Recruiting

Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

Chronic Myeloid Leukemia | Tyrosine Kinase Inhibitors

France
Medical College of Wisconsin
H. Jean Khoury Cure CML Consortium

Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia

United States
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Germany
Capital Medical University

Recruiting

A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza A

Influenza A

China
Sichuan University

Recruiting

Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II (WU-KONG36)

Non Small Cell Lung Cancer

China
Massachusetts General Hospital
Foundation Medicine

Recruiting

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

Melanoma | Non-small Cell Lung Cancer

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Non-Small Cell Lung Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

NSCLC | EGFR Gene Mutation

China
Frantz Viral Therapeutics, LLC
The Cleveland Clinic

Recruiting

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) (ART-VIN IIB)

Vulvar Diseases | HPV Infection | Vulvar HSIL | High Grade Intraepithelial Neoplasia | HPV Disease | Pre-Cancerous Dysplasia | Vin II | Vin III | VIN, Usual Type | VIN 2 of Usual Type | VIN 3 of Usual Type | VIN Grade 2 | VIN Grade 3

United States
Degan Lu
Wu Jieping Medical Foundation

Not yet recruiting

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Lung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
Centre Hospitalier Universitaire Dijon

Not yet recruiting

TocilizuMab discontinuAtion in GIant Cell Arteritis (MAGICA)

Giant Cell Arteritis

France
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Renal Cell Carcinoma
University Hospital Birmingham

Recruiting

The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Quality Of Life (GAMBOL Study) (GAMBOL)

Adult Growth Hormone Deficiency

United Kingdom
University of Miami

Recruiting

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer (Free-HER)

Stage IV Breast Cancer | HER2-positive Metastatic Breast Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...
Fundacion Clinic per a la Recerca Biomédica; Newcastle University; University...

Recruiting

Dissecting the Cellular and Molecular Atlas of Rheumatoid Arthritis in Sustained Remission to Identify Pathways Maintaining Remission and Triggering Flares (FLARE-RA)

Rheumatoid Arthritis

Italy, Spain, United Kingdom
Fundaleu

Recruiting

Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase (AST)

CML

Argentina
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
4th Military Clinical Hospital with Polyclinic,...

Recruiting

Comparison of the Efficacy and Safety of Cardioneuroablation to Permanent Pacing in Patients With an Implanted Pacemaker for Symptomatic Bradycardia. (GENTLE-PACE)

Bradycardia | Syncope

Poland
University College Cork
Cancer Research@UCC

Recruiting

Discontinuation Study

Cancer | Multiple Myeloma | Hematologic Cancer

Ireland
Fujian Cancer Hospital

Recruiting

HRQOL in Locally Advanced Thyroid Carcinoma (LATCQOL)

Thyroid Cancer | Health Related Quality of Life | Tyrosine Kinase Inhibitor

China
University Health Network, Toronto

Not yet recruiting

Short Antibiotic Treatment in High Risk Febrile Neutropenia

Febrile Neutropenia
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Non-small Cell Lung Cancer

China
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
Second Xiangya Hospital of Central South University
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (PRECISE)

Lung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary Resistance

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Fujian Cancer Hospital

Not yet recruiting

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Insel Gruppe AG, University Hospital Bern
University of Bern

Recruiting

STREAM Trial - Biomarker (STREAM-Bio)

Statin Treatment for Primary Prevention

Switzerland
Insel Gruppe AG, University Hospital Bern
University of Bern

Recruiting

STREAM Trial - Subclinical Atherosclerosis (STREAM-SubATS)

Statin Treatment for Primary Prevention

Switzerland
Lantern Pharma Inc.

Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis (METRO)

Idiopathic Retroperitoneal Fibrosis

France
University of British Columbia
Centre for Addiction and Mental Health; Canadian Institutes of Health Research... and other collaborators

Recruiting

Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study

Major Depressive Disorder, Recurrent, in Remission

Canada
Tongji Hospital

Recruiting

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

Hepatocellular Carcinoma | Effects of Immunotherapy | Programmed Cell Death 1

China
Institute of Mother and Child, Warsaw, Poland
Maria Sklodowska-Curie National Research Institute of Oncology

Recruiting

Regorafenib in Patients With Refractory Primary Bone Tumors (Regbone)

Osteosarcoma | Ewing Sarcoma of Bone

Poland
The First Affiliated Hospital of Zhengzhou University
BeiGene; Jiangsu Hengrui Pharmaceutical Co., Ltd.; RemeGen Co., Ltd.

Not yet recruiting

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

HER2-positive or Mutated Advanced Colorectal Cancer
Shenzhen Second People's Hospital

Recruiting

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Chronic Myeloid Leukemia, Chronic Phase | Olverembatinib | Tyrosine Kinase Inhibitors

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colorectal Neoplasms Malignant

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Universitätsklinikum Hamburg-Eppendorf
University Hospital, Essen; Philipps University Marburg Medical Center; Helmut...

Recruiting

Disentangling Pharmacological and Expectation Effects in Antidepressant Discontinuation (PHEA)

Depressive Symptoms | Expectations | Antidepressants

Germany
University Hospital Inselspital, Berne
University of Bern

Recruiting

STREAM Trial - Statins in Multimorbid Older Adults Without Cardiovascular Disease (STREAM)

Statin Treatment for Primary Prevention

Switzerland
Fudan University

Recruiting

The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Pancreatic Cancer

China
Affiliated Hospital of Nantong University

Recruiting

FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia (NTU-CML-001)

CML | Treatment-free Remission | Folate

China
Atsushi Kawakami
AbbVie GK.

Recruiting

Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate (DOPPLER)

Rheumatoid Arthritis | Biomarker | JAK Inhibitor | Musculoskeletal Ultrasound

Japan
AIO-Studien-gGmbH
AstraZeneca

Recruiting

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE)

NSCLC | EGFR Positive Non-small Cell Lung Cancer | Oligoprogression

Germany

Search clinical trials for: discontinuation treatment TKI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations